Amgen Inc

Amgen is a leading biopharmaceutical company that specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. With a broad portfolio of products that span multiple therapeutic areas, including oncology, inflammation, bone health, cardiovascular disease, and neuroscience, Amgen is dedicated to improving the lives of patients around the world.

With a presence in over 20 countries, Amgen's products are marketed in more than 100 countries globally. The company's commitment to research and development has led to the development of numerous innovative medicines, including the biologic Enbrel, which is used to treat inflammatory conditions and has been a significant contributor to the company's success.

Amgen is also committed to corporate social responsibility and investing in initiatives that improve the health and well-being of communities worldwide. The company's social responsibility initiatives include supporting patient access to healthcare, improving science education, promoting environmental sustainability, and investing in community health programs.

Amgen was established in Thousand Oaks, California on April 8, 1980, by venture capitalists William K. (Bill) Bowes and associates. The company's original name was Applied Molecular Genetics, which became the official name of the company in 1983.

Initially, Amgen focused on developing innovative biologic drugs for the treatment of serious illnesses, including cancer, immune disorders, and anaemia. In 1984, the company launched its first product, Epogen, which was used to treat anaemia caused by chronic kidney disease.

In the following years, Amgen continued to develop and launch new products, including Neupogen, which stimulates white blood cell production to boost the immune system, and Aranesp, a longer-acting version of Epogen for the treatment of anaemia. The company also expanded its research and development efforts and made significant investments in biotechnology companies, further strengthening its position in the industry.

In 2002, Amgen acquired the biotechnology company Immunex Corporation, gaining access to its products, including Enbrel, a biologic drug used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis.

In recent years, Amgen has continued to focus on research and development, launching new products for the treatment of cancer, osteoporosis, and other serious illnesses. The company has also made strategic acquisitions, including the acquisition of deCODE Genetics, a company specializing in genomic research.

Today, Amgen is one of the world's largest biopharmaceutical companies, with a presence in more than 100 countries and a broad portfolio of products that span multiple therapeutic areas. The company has remained committed to its mission of developing innovative medicines and improving the lives of patients worldwide.

The mission of Amgen is to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives. The company is dedicated to discovering, developing, and delivering innovative therapies that address unmet medical needs and improve the quality of life for patients around the world. Amgen's goal is to provide access to these therapies and make a meaningful difference in the lives of those who need them. The company is committed to advancing science, fostering collaboration, and operating with integrity, to help people live longer, healthier lives.

Amgen's vision is to create value through innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases. Their core values are to be science-based, compete intensely and win, create value, be ethical, trust and respect, teamwork and quality.

Amgen is a biopharmaceutical company that specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company has a broad portfolio of products that span multiple therapeutic areas, including oncology, inflammation, bone health, cardiovascular disease, and neuroscience. Here are some of Amgen's key products and services:

1. Oncology: Amgen offers a range of innovative therapies for the treatment of cancer. These include Kyprolis, a treatment for multiple myeloma, and Imlygic, a genetically modified oncolytic viral therapy for melanoma.

2. Inflammation: Amgen's portfolio includes several biologic drugs that target inflammatory diseases such as rheumatoid arthritis and psoriasis. These include Enbrel, which has been a significant contributor to the company's success, and Otezla, which was acquired through the acquisition of Celgene.

3. Bone Health: Amgen offers a range of products for the treatment of bone diseases such as osteoporosis. These include Prolia, which is used to treat bone loss in patients with prostate or breast cancer, and Xgeva, which is used to prevent bone fractures in patients with cancer that has spread to the bone.

4. Cardiovascular Disease: Amgen's cardiovascular disease portfolio includes Repatha, a biologic drug used to lower cholesterol levels in patients with hypercholesterolemia or cardiovascular disease.

5. Neuroscience: Amgen is developing a number of innovative therapies for the treatment of neurological disorders, including migraine and Alzheimer's disease. These include Aimovig, a biologic drug used to prevent migraines, and AMG 510, a small molecule drug in development for the treatment of certain types of solid tumors.

In addition to its product portfolio, Amgen offers a range of services to support patient access to its medicines. These include patient assistance programs, reimbursement support, and educational resources for healthcare providers and patients. Overall, Amgen's products and services are focused on improving the lives of patients worldwide through innovative and effective therapies for serious illnesses.